New Arthritis Drug Prevents Joint Damage

Friday, 22 Nov 2013 12:27 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

A potential rheumatoid arthritis treatment from French drugmaker Sanofi and its U.S. development partner Regeneron Pharmaceuticals Inc. fared better than a fake drug at improving disease signs and symptoms in a late-stage study.
 
The companies said Friday they saw a statistically significant improvement in patient groups that received their drug, sarilumab, combined with methotrexate compared to those who just received methotrexate and a placebo.
 
About 1,200 patients enrolled in the study. Researchers tested two doses of the drug in adults with active rheumatoid arthritis who were not helped by methotrexate.

Editor's note: 3 Signs You’re Close to a Heart Attack
 
Aside from improving signs and symptoms, the treatment also helped physical function and inhibited joint damage progression, the companies said.
 
Rheumatoid arthritis is a chronic inflammatory disease that affects the joints and destroys soft tissue, cartilage and bone. It represents a major area of research for drug companies because it is chronic, meaning patients will likely take the drugs regularly for a long time.
 
Last year, the Food and Drug Administration approved a new treatment for the disease, Pfizer Inc.'s twice-a-day pill Xeljanz.
 

© Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Kids' Get Antibiotics Twice as Often as Needed: Study

Monday, 15 Sep 2014 17:09 PM

Pediatricians prescribe antibiotics about twice as often as they're actually needed for children with ear and throat inf . . .

Bald Men Have Higher Prostate Cancer Risk: Study

Monday, 15 Sep 2014 17:01 PM

Men with male pattern baldness may face a higher risk of developing an aggressive type of prostate cancer than men with  . . .

Drugmaker Agrees to Cheaper Versions of $1,000-a-Pill Hepatitis Med

Monday, 15 Sep 2014 16:51 PM

U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will s . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved